Novel CD20 monoclonal antibodies for lymphoma therapy-Reference-Cited by-同舟云学术

Novel CD20 monoclonal antibodies for lymphoma therapy

Published:2012-10-11 Issue:1 Volume:5 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Cang Shundong,Mukhi Nikhil,Wang Kemeng,Liu Delong

Abstract

Abstract Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin’s lymphoma (NHL). Novel agents are under active clinical trials. This review will summarize the latest development in new mAbs against CD20, which include second-generation mAbs, ofatumumab, veltuzumab (IMMU-106), ocrelizumab (PRO70769), and third-generation mAbs, AME-133v (ocaratuzumab), PRO131921 and GA101 (obinutumumab).

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

https://link.springer.com/content/pdf/10.1186/1756-8722-5-64.pdf

Reference116 articles.

1. Coiffier B: Rituximab in the treatment of diffuse large B-cell lymphomas. Semin Oncol. 2002, 29 (1 Suppl 2): 30-35.

2. Coiffier B: Rituximab in diffuse large B-cell lymphoma. Clin Adv Hematol Oncol. 2004, 2 (3): 156-157.

3. Coiffier B: Rituximab and CHOP-like chemotherapy in good-prognosis diffuse large-B-cell lymphoma. Nature clinical practice Oncology. 2006, 3 (11): 594-595.

4. Coiffier B: Rituximab therapy in malignant lymphoma. Oncogene. 2007, 26 (25): 3603-3613. 10.1038/sj.onc.1210376.

5. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002, 346 (4): 235-242. 10.1056/NEJMoa011795.

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients;BMC Immunology;2024-01-13

2. Therapeutic options for rituximab-resistant patients;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

3. Therapeutic antibodies against cancer—A step toward the treatment;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

4. Changing Trends in B-Cell Non-Hodgkin Lymphoma Treatment: The Role of Novel Monoclonal Antibodies in Clinical Practice;Cancers;2023-11-13

5. The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience;Leukemia & Lymphoma;2023-10-27